• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA approves Bracco’s contrast agent for pediatric CNS imaging

January 30, 2018 By Sarah Faulkner

BraccoThe FDA has approved a label change to Bracco Diagnostics‘ MultiHance MRI contrast agent. The company’s product can now be used to visualize lesions with abnormal vascularity of the brain and spine in patients younger than two years old.

Data collected in pediatric patients under the age of two showed that a dose of 0.05 mmol/kg is effective at boosting the visualization of lesions in the brain and spine. Older kids and adults, however, need a dose of 0.1 mmol/kg.

“The approval of use of MultiHance in younger pediatric patients, including term neonates, reflects the review made by the Food and Drug Administration (FDA) of the safety and efficacy of MultiHance in that special patient population,” Dr. Alberto Spinazzi, SVP & head of global medical & regulatory affairs at Bracco Group, said in prepared remarks. “The FDA approval means that the benefit-risk ratio of MultiHance use in MRI of the CNS is positive also in neonates and infants, as it is in older subjects.”

“This approval is a testament of our commitment to provide new and expanded indications for this class of products, with special efforts aimed to benefit patients with this specialized need,” president & CEO Vittorio Puppo added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Imaging, Neurological, Pediatrics, Regulatory/Compliance Tagged With: Bracco Diagnostics

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS